Patient Square Capital LP Trims Stock Position in Pharvaris (NASDAQ:PHVS)

Patient Square Capital LP decreased its position in Pharvaris (NASDAQ:PHVS) by 14.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 207,603 shares of the company’s stock after selling 34,738 shares during the period. Pharvaris accounts for about 1.5% of Patient Square Capital LP’s investment portfolio, making the stock its 12th biggest position. Patient Square Capital LP’s holdings in Pharvaris were worth $3,980,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Barclays PLC purchased a new position in Pharvaris during the 3rd quarter valued at about $106,000. JPMorgan Chase & Co. boosted its stake in shares of Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock valued at $59,000 after purchasing an additional 2,847 shares in the last quarter. Legal & General Group Plc increased its holdings in Pharvaris by 11.2% during the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company’s stock valued at $189,000 after buying an additional 994 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Pharvaris during the fourth quarter worth $111,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Pharvaris by 36.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock worth $8,510,000 after buying an additional 118,408 shares during the period.

Pharvaris Stock Down 4.2%

NASDAQ PHVS opened at $16.11 on Wednesday. Pharvaris has a 52 week low of $11.51 and a 52 week high of $25.50. The company has a 50 day moving average price of $15.32 and a 200 day moving average price of $17.79. The firm has a market cap of $842.39 million, a PE ratio of -5.75 and a beta of -2.85.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Monday, April 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.06. On average, equities research analysts anticipate that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PHVS has been the topic of several recent research reports. JMP Securities increased their target price on Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research report on Friday, January 31st. Cantor Fitzgerald assumed coverage on Pharvaris in a research report on Tuesday, April 29th. They set an “overweight” rating and a $28.00 price objective on the stock.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.